Celera Licenses Decode Gene Markers to Grow Cardiovascular Dx Franchise

The deal will give cash-strapped Decode immediate access to an undisclosed sum in upfront payments, while Celera will gain access to gene markers that will expand its cardiovascular disease-focused genetic testing service.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories